Safety and immunogenicity of palivizumab (Synagis) administered for two seasons
- PMID: 16282947
- DOI: 10.1097/01.inf.0000183938.33484.bd
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons
Abstract
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
Similar articles
-
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.BMC Pediatr. 2010 Jun 3;10:38. doi: 10.1186/1471-2431-10-38. BMC Pediatr. 2010. PMID: 20525274 Free PMC article. Clinical Trial.
-
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.Pediatr Infect Dis J. 1998 Sep;17(9):787-91. doi: 10.1097/00006454-199809000-00007. Pediatr Infect Dis J. 1998. PMID: 9779762 Clinical Trial.
-
[Prevention of respiratory syncytial virus bronchiolitis].Arch Pediatr. 2006 Dec;13 Suppl 5:S12-7. doi: 10.1016/s0929-693x(06)80011-4. Arch Pediatr. 2006. PMID: 17550819 French. No abstract available.
-
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007743. doi: 10.1002/14651858.CD007743.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007743. doi: 10.1002/14651858.CD007743.pub3 PMID: 20166098 Updated. Review.
-
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.Expert Opin Biol Ther. 2007 Sep;7(9):1471-80. doi: 10.1517/14712598.7.9.1471. Expert Opin Biol Ther. 2007. PMID: 17727335 Review.
Cited by
-
Palivizumab for the prevention of respiratory syncytial virus infection.Can Fam Physician. 2010 Aug;56(8):769-72. Can Fam Physician. 2010. PMID: 20705882 Free PMC article.
-
Infectious complications associated with monoclonal antibodies and related small molecules.Clin Microbiol Rev. 2009 Apr;22(2):274-90, Table of Contents. doi: 10.1128/CMR.00040-08. Clin Microbiol Rev. 2009. PMID: 19366915 Free PMC article. Review.
-
Prevention of respiratory syncytial virus infection.Paediatr Child Health. 2009 Oct;14(8):521-32. doi: 10.1093/pch/14.8.521. Paediatr Child Health. 2009. PMID: 20885804 Free PMC article.
-
Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.PLoS One. 2015 Aug 3;10(8):e0134711. doi: 10.1371/journal.pone.0134711. eCollection 2015. PLoS One. 2015. PMID: 26237402 Free PMC article.
-
Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants.Ital J Pediatr. 2014 Oct 24;40:65. doi: 10.1186/1824-7288-40-65. Ital J Pediatr. 2014. PMID: 25344148 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical